Zhejiang Haisen Pharmaceutical Co., Ltd. (SHE:001367)
China · Delayed Price · Currency is CNY 20.44
-1.36 (-6.24%)
At close: Aug 24, 2026
SHE:001367 Revenue
Zhejiang Haisen Pharmaceutical had revenue of 143.70M CNY in the quarter ending June 30, 2026, with 16.25% growth. This brings the company's revenue in the last twelve months to 541.06M, up 7.58% year-over-year. In the year 2025, Zhejiang Haisen Pharmaceutical had annual revenue of 532.26M with 12.88% growth.
Revenue (ttm)
541.06M
Revenue Growth
+7.58%
P/S Ratio
5.68
Revenue / Employee
767.47K
Employees
705
Market Cap
3.07B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 532.26M | 60.75M | 12.88% |
| Dec 31, 2024 | 471.51M | 74.06M | 18.63% |
| Dec 31, 2023 | 397.45M | -25.32M | -5.99% |
| Jan 1, 2023 | 422.78M | 33.79M | 8.69% |
| Dec 31, 2021 | 388.98M | 104.18M | 36.58% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Zhejiang Int'l Group | 33.84B |
| Shanghai Shenqi Pharmaceutical Investment Management | 1.90B |
| Zhejiang Zhenyuan Share | 1.86B |
| GuangYuYuan Chinese Herbal Medicine | 1.44B |
| Hangzhou Minsheng Healthcare | 827.65M |
| Chongqing Lummy Pharmaceutical | 748.94M |
| Hangzhou Bio-Sincerity Pharma-Tech | 709.72M |
| Hubei Guangji Pharmaceutical | 638.58M |